Circio's circVec Technology Achieves 40x Enhancement in AAV Gene Therapy Vectors
Key Insights
Circio's circVec (search)-AAV (search) expression system demonstrates up to 40 times enhanced protein expression compared to conventional mRNA-based AAV vectors in heart and eye tissues.
The new circVec (search) 3.2 design achieves 3x increased expression levels versus previous circVec generations, potentially enabling 10-fold or greater viral dose reduction.
The circular RNA-based technology addresses key safety concerns and cost challenges in AAV (search) gene therapy by reducing required dosing levels.
Circio Holding ASA (search) has announced breakthrough results for its circVec (search)-AAV (search) expression system, demonstrating up to 40 times enhanced activity compared to conventional mRNA-based adeno-associated virus (AAV) vectors. The Norwegian biotechnology company presented the strengthened in vivo data on August 28, 2025, showcasing significant potential for improving gene therapy efficacy while addressing critical safety and cost challenges.
Enhanced Performance Across Multiple Tissues
The latest circVec (search) generation 3.2 design achieves 3x increased expression levels compared to previous circVec generations specifically in AAV (search) gene therapy vectors. In heart tissue, the technology delivers up to 40 times protein expression level advantage versus conventional mRNA-AAV, validating earlier encouraging data presented in May 2025 through larger in vivo repeat experiments.
Circio has identified the eye as another promising target organ, showing 15 times expression advantage compared to benchmark AAVs. The company is currently conducting broader in vivo testing across several other tissues, with results expected during the second half of 2025.
Addressing Critical AAV Gene Therapy Challenges
Dr. Thomas B Hansen, CTO of Circio, emphasized the clinical significance of these findings: "A major challenge of conventional mRNA-based AAV (search) gene therapy is the need for extremely high dose levels. This can cause severe toxicity in patients and drives up manufacturing cost and complexity. Our current data package suggests that switching to circVec (search)-based expression may enable 10-fold, or more, dose reduction, which would be a major breakthrough for the AAV gene therapy field."
The circular RNA-based expression system has the potential to substantially improve the therapeutic potency of AAV (search) vectors in a tissue-specific manner, creating multiple distinct development opportunities for the circVec (search) platform.
Comprehensive Technology Validation
Circio has completed substantial characterization, engineering and optimization of its circVec (search) expression system for gene therapy. The latest circVec-AAV (search) in vivo results confirm that the robust circVec advantage applies broadly across several tissues, additional AAV capsids and multiple genetic promoters driving expression.
Dr. Lubor Gaal, CFO of Circio, noted: "These results broaden and strengthen Circio's data package, and derisks the technology for potential partners and investors. Our aim is to leverage these new data to establish R&D collaborations with AAV (search) expert companies and validate the performance of the circVec (search) platform in their systems."
Strategic Partnerships and Financial Position
The company has ongoing dialogues with potential partners and aims to enter multiple R&D collaborations during 2025-26. Circio continues to implement tight cost controls with a lean organizational setup, strictly prioritizing R&D activities that can deliver near-term technology validation and business development opportunities.
The extension of financing commitment by Atlas Capital Markets (search) secures funding until the end of 2025, while the company explores multiple alternatives to secure new capital and strengthen its shareholder base to minimize reliance on convertible bond facilities.